Ph 2 study of BND-22 (SAR444881) + anti-PD-1 therapy in IO-refractory NSCLC or IO-naive MSS-CRC or ovarian cancer to be initiated October 16, 2025
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 October 7, 2025
New Ph 2 Data for Stenoparib/2X-121 Showed Landmark Median OS Surpassing 25 Months September 23, 2025
IMNN-001 Ph 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift September 23, 2025
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Previously Treated with Bevacizumab September 16, 2025
FDA accepted relacorilant NDA for patients with platinum-resistant ovarian cancer; PDUFA date: Jul 11, 2026 September 16, 2025
Clinical development of ZW171 to be discontinued in gynecological, thoracic, and digestive system cancers September 3, 2025
FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer September 3, 2025
Hong Kong Department of Health approves TIVDAK (tisotumab vedotin-tftv) in Hong Kong for patients with recurrent or metastatic cervical cancer September 3, 2025
First Patient Dosed in Ph 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer August 5, 2025
Final Clinical Data Update from the NXP800 Ph 1b Study in Ovarian Cancer Provided and Completion of the NXP900 Ph 1a Dose Escalation Study Reported August 5, 2025
LIfT BioSciences granted €12M from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy August 5, 2025
Clinical Evaluation of SON-1010 Dose Escalation Expanded with Atezolizumab in Ovarian Cancer August 5, 2025
JSKN003 Received FDA IND Approval to Initiate Ph 2 Study for Platinum-Resistant Ovarian Cancer August 5, 2025
First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer July 29, 2025
NDA submitted for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer July 15, 2025
Primary Results from Ph 2 RAMP 201 Trial of Avutometinib + Defactinib combo in Patients with Recurrent Low-Grade Serous Ovarian Cancer published in JCO July 15, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 8, 2025
Data from Ongoing Dose Escalation of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma presented July 8, 2025
First Patient Dosed with Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab July 1, 2025
Second patient dosed in Ph 2 trial protocol of stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer July 1, 2025
Results from Ph 1 FRAME Study of Avutometinib + Defactinib combo in Solid Tumors, including Low-Grade Serious Ovarian Cancer, published in Nature Medicine July 1, 2025
